Cardiogenic Shock
1
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AbbottABBOTT PARK, IL
3 programs1
LevosimendanPhase 2/31 trial
HeartMate PHPN/A1 trial
VasopressorN/A1 trial
Active Trials
TM
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
AbbottLevosimendan
Teleflex MedicalIntra-Aortic Balloon Pump
AbbottVasopressor
ZollIVTM™ System
AbbottHeartMate PHP
Clinical Trials (5)
Total enrollment: 5,049 patients across 5 trials
Levosimendan Versus Dobutamine in Shock Patients
Start: Oct 2004Est. completion: Apr 200640 patients
Phase 2/3Unknown
Clinical Effects of Intra-aortic Balloon Support in Early Acute Coronary Syndrome and Non-Acute Coronary Syndrome Related Cardiogenic Shock
Start: Jun 2024Est. completion: Jun 2027
N/ANot Yet Recruiting
Cardiogenic Shock Working Group Registry
Start: Dec 2017Est. completion: Jun 20265,000 patients
N/ARecruiting
Cardiogenic Shock Intravascular Cooling Trial
Start: Nov 2017Est. completion: Nov 2021
N/ACompleted
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
Start: Oct 2014Est. completion: Jan 20179 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 5,049 patients
4 companies competing in this space